A Study of Olverembatinib in the Treatment of Ph+ ALL
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of a novel third-generation
TKI Olverembatinib.
The main purpose of the study is to evaluate the efficacy and safety of Olverembatinib in Ph+
ALL patients.